Oral Administration of Saccharomyces boulardii Ameliorates Carbon Tetrachloride-Induced Liver Fibrosis in Rats via Reducing Intestinal Permeability and Modulating Gut Microbial Composition

Inflammation

Volumn 38, Issue 1, 2015, Pages 170-179

  Li, Ming ^a   Zhu, Lin ^a   Xie, Ao ^a   Yuan, Jieli ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

endotoxin; liver fibrosis; pro inflammatory cytokines; Saccharomyces boulardii

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA SMOOTH MUSCLE ACTIN; ASPARTATE AMINOTRANSFERASE; CARBON TETRACHLORIDE; COLLAGEN TYPE 1; COLLAGEN TYPE 1A1; DRUG TOXICITY; ENDOTOXIN; FUNGAL EXTRACT; MALONALDEHYDE; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANIMAL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTAGONISTS AND INHIBITORS; ARTICLE; CARBON TETRACHLORIDE-INDUCED LIVER FIBROSIS; CHEMICALLY INDUCED; CONTROLLED STUDY; DENATURING GRADIENT GEL ELECTROPHORESIS; DRUG EFFECTS; INTESTINE; INTESTINE ABSORPTION; INTESTINE FLORA; INTESTINE MUCOSA PERMEABILITY; LIVER CIRRHOSIS; LIVER HISTOLOGY; MALE; METABOLISM; MICROBIOLOGY; MICROFLORA; NONHUMAN; ORAL DRUG ADMINISTRATION; PERMEABILITY; PHYSIOLOGY; PREVENTION; QUANTITATIVE ANALYSIS; RAT; REAL TIME POLYMERASE CHAIN REACTION; SACCHAROMYCES; SACCHAROMYCES BOULARDII; WISTAR RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTAGONISTS AND INHIBITORS; CARBON TETRACHLORIDE; CHEMICALLY INDUCED; DRUG EFFECTS; INTESTINAL ABSORPTION; INTESTINES; LIVER CIRRHOSIS; MALE; METABOLISM; MICROBIOLOGY; MICROBIOTA; PERMEABILITY; PHYSIOLOGY; PREVENTION AND CONTROL; RATS; RATS, WISTAR; SACCHAROMYCES; TOXICITY;

RATTUS; RATTUS NORVEGICUS; SACCHAROMYCES BOULARDII;

EID: 84964211538     PISSN: 03603997     EISSN: 15732576     Source Type: Journal    
DOI: 10.1007/s10753-014-0019-7     Document Type: Article

References (41)

1. El Bialy, S.A., K.F. El Kader, and M.B. El-Ashmawy. 2011. Current progress in antifibrotics. Current Medicinal Chemistry 18: 3082–3092.
2. Friedman, S.L. 2004. Mechanisms of disease: mechanisms of hepatic fibrosis and therapeutic implications. Nature Clinical Practice Gastroenterology and Hepatology 1: 98–105.
3. Friedman, S.L., F.J. Roll, J. Boyles, et al. 1985. Hepatic lipocytes: the principal collagen-producing cells of normal rat liver. Proceedings of the National Academy of Sciences of the United States of America 82: 8681–8685.
4. Friedman, S.L., and M.B. Bansal. 2006. Reversal of hepatic fibrosis—fact or fantasy? Hepatology 43: S82–S88.
5. Chen, Y., F. Yang, H. Lu, B. Wang, et al. 2011. Characterization of fecal microbial communities in patients with liver cirrhosis. Hepatology 54: 562–572.
6. Cesaro, C., A. Tiso, A. Del Prete, R. Cariello, et al. 2011. Gut microbiota and probiotics in chronic liver diseases. Digestive and Liver Disease 43: 431–438.
7. Guerrero Hernandez, I., A. Torre Delgadillo, F. Vargas Vorackova, et al. 2008. Intestinal flora, probiotics, and cirrhosis. Annals of Hepatology 7: 120–124.
8. Zhang, W., Y. Gu, Y. Chen, et al. 2010. Intestinal flora imbalance results in altered bacterial translocation and liver function in rats with experimental cirrhosis. European Journal of Gastroenterology and Hepatology 22: 1481–1486.
9. Graff, S., J.C. Chaumeil, P. Boy, R. Lai-Kuen, et al. 2008. Influence of pH conditions on the viability of Saccharomyces boulardii yeast. The Journal of General and Applied Microbiology 54: 221–227.
10. Edwards-Ingram, L., P. Gitsham, N. Burton, et al. 2007. Genotypic and physiological characterization of Saccharomyces boulardii, the probiotic strain of Saccharomyces cerevisiae. Applied and Environmental Microbiology 73: 2458–2467.
11. Kelesidis, T., and C. Pothoulakis. 2012. Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders. Therapeutic Advances in Gastroenterology 5: 111–125.
12. Can, M., B.A. Besirbellioglu, I.Y. Avci, et al. 2006. Prophylactic Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea: a prospective study. Medical Science Monitor: International Medical Journal of Experimental and Clinical Research 12: 19–22.
13. McFarland, L.V. 2010. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World Journal of Gastroenterology 16: 2202–2222.
14. Schneider, S.M., F. Girard-Pipau, J. Filippi, et al. 2005. Effects of Saccharomyces boulardii on fecal short-chain fatty acids and microflora in patients on long-term total enteral nutrition. World Journal of Gastroenterology 11: 6165–6169.
15. Leonel, A.J., and J.I. Alvarez-Leite. 2012. Butyrate: implications for intestinal function. Current Opinion in Clinical Nutrition and Metabolic Care 15: 474–479.
16. Everard, A., S. Matamoros, L. Geurts, et al. 2014. Saccharomyces boulardii administration changes gut microbiota and reduces hepatic steatosis, low-grade inflammation, and fat mass in obese and type 2 diabetic db/db mice. mBio 5(3): e01011–e01014.
17. Clawson, G.A. 1989. Mechanisms of carbon tetrachloride hepatotoxicity. Pathology and Immunopathology Research 8: 104–112.
18. Sanchez, E., J. C. Nieto, A. Boullosa, et al. 2014. VSL#3 probiotic treatment decreases bacterial translocation in rats with carbon tetrachloride-induced cirrhosis. Liver International Article first published online: 12 MAY 2014 doi: 10.1111/liv.12566.
19. D'Argenio, G., R. Cariello, C. Tuccillo, et al. 2013. Symbiotic formulation in experimentally induced liver fibrosis in rats: intestinal microbiota as a key point to treat liver damage? Liver International 33: 687–697.
20. Affò, S., O. Morales-Ibanez, D. Rodrigo-Torres, et al. 2014. CCL20 mediates lipopolysaccharide induced liver injury and is a potential driver of inflammation and fibrosis in alcoholic hepatitis. Gut Article first published online: 12 AUG 2014 doi:10.1136/gutjnl-2013-306098.
21. Yagi, K., S. Matsuoka, A.W. Linnane, et al. 1981. Plasma lipid peroxide levels in an urbanized Micronesian population—Nauru. Journal of Nutritional Science and Vitaminology 27: 425–428.
22. Satoh, K., S. Takamatsu, S. Sakuta, et al. 1981. Augmented malondialdehyde production by platelets from patients with cerebrovascular disorders. Japanese Circulation Journal 45: 1335–1341.
23. Poyrazoglu, O.K., I.H. Bahcecioglu, H. Ataseven, et al. 2008. Effect of unfiltered coffee on carbon tetrachloride-induced liver injury in rats. Inflammation 31: 408–413.
24. Lee, I.H., A. Dinudom, A. Sanchez-Perez, et al. 2007. Akt mediates the effect of insulin on epithelial sodium channels by inhibiting Nedd4-2. The Journal of Biological Chemistry 282: 29866–29873.
25. Joossens, M., G. Huys, M. Cnockaert, et al. 2011. Dysbiosis of the fecal microbiota in patients with Crohn's disease and their unaffected relatives. Gut 60: 631–637.
26. Liu, Y., T. Zhou, D. Crowley, et al. 2012. Decline in topsoil microbial quotient, fungal abundance and C utilization efficiency of rice paddies under heavy metal pollution across South China. PLoS ONE 7: e38858.
27. Penders, J., C. Thijs, C. Vink, et al. 2006. Factors influencing the composition of the intestinal microbiota in early infancy. Pediatrics 118: 511–521.
28. Salzman, N.H., H. Kuiechun, D. Haribhai, et al. 2010. Enteric defensins are essential regulators of intestinal microbial ecology. Nature Immunology 11: 76–82.
29. Bartosch, S., A. Fite, G.T. Macfarlane, et al. 2004. Characterization of bacterial communities in feces from healthy elderly volunteers and hospitalized elderly patients by using real-time PCR and effects of antibiotic treatment on the fecal microbiota. Applied and Environmental Microbiology 70: 3575–3581.
30. Wiest, R., F. Chen, G. Cadelina, et al. 2003. Effect of Lactobacillus-fermented diets on bacterial translocation and intestinal flora in experimental prehepatic portal hypertension. Digestive Diseases and Sciences 48: 1136–1141.
31. Soriano, G., E. Sanchez, C. Guarner, et al. 2012. Lactobacillus johnsonii La1 without antioxidants does not decrease bacterial translocation in rats with carbon tetrachloride-induced cirrhosis. Journal of Hepatology 57: 1395–1396.
32. Rincon, D., J. Vaquero, A. Hernando, et al. 2014. Oral probiotic vsl#3 attenuates the circulatory disturbances of patients with cirrhosis and ascites. Liver International Article first published online: 4 APR 2014 doi: 10.1111/liv.12539.
33. Dapito, D.H., A. Mencin, G.Y. Gwak, et al. 2012. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell 21(4): 504–516.
34. Chan, C.C., S.J. Hwang, F.Y. Lee, et al. 1997. Prognostic value of plasma endotoxin levels in patients with cirrhosis. Scandinavian Journal of Gastroenterology 32: 942–946.
35. Rietschel, E.T., T. Kirikae, F.U. Schade, et al. 1994. Bacterial endotoxin: molecular relationships of structure to activity and function. FASEB Journal 8: 217–225.
36. Raetz, C.R., and C. Whitfield. 2002. Lipopolysaccharide endotoxins. Annual Review of Biochemistry 71: 635–700.
37. Schnabl, B., and D.A. Brenner. 2014. Interactions between the intestinal microbiome and liver diseases. Gastroenterology 146: 1513–1524.
38. 4-induced fibrosis. PLoS ONE 6: e23037.
39. Plummer, J.L., C.J. Ossowicz, C. Whibley, et al. 2000. Influence of intestinal flora on the development of fibrosis and cirrhosis in a rat model. Journal of Gastroenterology and Hepatology 15: 1307–1311.
40. Riordan, S.M., and R. Williams. 2006. The intestinal flora and bacterial infection in cirrhosis. Journal of Hepatology 45: 744–757.
41. Llovet, J.M., R. Bartoli, F. March, et al. 1998. Translocated intestinal bacteria cause spontaneous bacterial peritonitis in cirrhotic rats: molecular epidemiologic evidence. Journal of Hepatology 28: 307–313.